Monitoring tobacco-specific N-nitrosamines and nicotine in novel Marlboro and Camel smokeless tobacco products: Findings from round 1 of the new product watch

Nicotine and Tobacco Research

Volumn 14, Issue 3, 2012, Pages 274-281

  Stepanov, Irina ^a,b   Biener, Lois ^c   Knezevich, Aleksandar ^a   Nyman, Amy L ^c   Bliss, Robin ^a   Jensen, Joni ^b   Hecht, Stephen S ^a,b   Hatsukami, Dorothy K ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; NITROSAMINE;

ARTICLE; CHEMICAL COMPOSITION; GEOGRAPHY; PH; PRIORITY JOURNAL; SMOKELESS TOBACCO; SUMMER; UNITED STATES;

EID: 84857661971     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntr209     Document Type: Article

References (28)

1. Advisory Committee to the Surgeon General. (1986). The health consequences of using smokeless tobacco. Bethesda, MD: U.S. Department of Health and Human Sciences. NIH Publication No. 86-2874.
2. Bartsch, H., & Spiegelhalder, B. (1996). Environmental exposure to N-nitroso compounds (NNOC) and precursors: An overview. European Journal of Cancer Prevention, 5, 11-18. doi:10.1097/00008469-199609001-00003.
3. Bates, C., Fagerstrom, K., Jarvis, M. J., Kunze, M., McNeill, A., & Ramstrom, L. (2003). European Union policy on smokeless tobacco: A statement in favor of evidence based regulation for public health. Tobacco Control, 12, 360-367. doi:10.1136/tc.12.4.360.
4. Biener, L., & Bogen, K. (2009). Receptivity to Taboka and Camel Snus in a U.S. test market. Nicotine & Tobacco Research, 11, 1154-1159. doi:10.1093/ntr/ntp113.
5. Biener, L., McCausland, K., Curry, L., & Cullen, J. (2011). Prevalence of trial of snus products among adult smokers. American Journal of Public Health. E-publication ahead of print (February 17, 2011). Retrieved from http://ajph.aphapublications.org/cgi/doi/10.2105/AJPH.2010.200097.
6. Fant, R. V., Henningfield, J. E., Nelson, R. A., & Pickworth, W. B. (1999). Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tobacco Control, 8, 387-392. doi:10.1136/tc.8.4.387.
7. Greer, R. O., Jr. (2011). Oral manifestations of smokeless tobacco use. Otolaryngologic Clinics of North America, 44, 31-56. doi:10.1016/j.otc.2010.09.002.
8. Hatsukami, D. K., Jensen, J., Anderson, A., Broadbent, B., Allen, S., Zhang, Y., et al. (in press). Oral tobacco products: Preference and effects among smokers. Drug and Alcohol Dependence, doi:10.1016/j.drugalcdep.2011.03.026.
9. Hatsukami, D. K., Lemmonds, C., & Tomar, S. L. (2004). Smokeless tobacco use: Harm reduction or induction approach? Preventive Medicine, 38, 309-317. doi:10.1016/j.ypmed.2003.10.006.
10. Hatsukami, D. K., & Severson, H. H. (1999). Oral spit tobacco: Addiction, prevention and treatment. Nicotine & Tobacco Research, 1, 21-44. doi:10.1080/14622299050011131.
11. Hecht, S. S. (1998). Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chemical Research in Toxicology, 11, 559-603. doi:10.1021/tx980005y.
12. Hecht, S. S., & Hoffmann, D. (1988). Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis, 9, 875-884. doi:10.1093/carcin/9.6.875.
13. Hecht, S. S., Rivenson, A., Braley, J., DiBello, J., Adams, J. D., & Hoffmann, D. (1986). Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. Cancer Research, 46, 4162-4166.
14. Henningfield, J. E., Fant, R. V., & Tomar, S. L. (1997). Smokeless tobacco: An addicting drug. Advances in Dental Research, 11, 330-335. doi:10.1177/08959374970110030401.
15. Hoffmann, D., & Djordjevic, M. V. (1997). Chemical composition and carcinogenicity of smokeless tobacco. Advances in Dental Research, 11, 322-329. doi:10.1177/08959374970110030301.
16. International Agency for Research on Cancer. (2007). Smokeless tobacco and tobacco-specific nitrosamines. In IARC monographs on the evaluation of carcinogenic risks to humans (Vol. 89, pp. 548-553). Lyon, France: IARC.
17. Kotlyar, M., Hertsgaard, L. A., Lindgren, B. R., Jensen, J. A., Carmella, S. G., Stepanov, I., et al. (2011). Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: A feasibility study. Cancer Epidemiology, Biomarkers & Prevention, 20, 91-100. doi:10.1158/1055-9965.EPI-10-0349.
18. Levy, D. T., Mumford, E. A., Cummings, K. M., Gilpin, E. A., Giovino, G., Hyland, A., et al. (2004). The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: Estimates of a panel of experts. Cancer Epidemiology, Biomarkers & Prevention, 13, 2035-2042.
19. Luo, J., Ye, W., Zandehdel, K., Adami, J., Adami, H. O., Boffetta, P., et al. (2007). Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: A retrospective cohort study. The Lancet, 369, 2015-2020. doi:10.1016/S0140-6736(07)60678-3.
20. Magee, P. N. (1996). Nitrosamines and human cancer: Introduction and overview. European Journal of Cancer Prevention, 5, 7-10. doi:10.1097/00008469-199609001-00002.
21. National Cancer Institute. (1992). Smokeless tobacco or health, an international perspective. Smoking and tobacco control monographs (pp. 96-106). Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health.
22. Preston-Martin, S., & Correa, P. (1989). Epidemiological evidence for the role of nitroso compounds in human cancer. Cancer Surveys, 8, 459-473.
23. Richter, P., & Spierto, F. W. (2003). Surveillance of smokeless tobacco nicotine, pH, moisture, and unprotonated nicotine content. Nicotine & Tobacco Research, 5, 885-889. doi:10.1080/14622200310001614647.
24. Rogers, J. D., Biener, L., & Clark, P. I. (2010). Test marketing of new smokeless tobacco products in four U.S. cities. Nicotine & Tobacco Research, 12, 69-72. doi:10.1093/ntr/ntp166.
25. Rogers, J. D., Biener, L., Nyman, A. L., & Crow, R. (February, 2010). Building a national surveillance infrastructure for new smokeless tobacco and nicotine products. Society for Research on Nicotine and Tobacco, Baltimore, MD.
26. Stepanov, I., Hecht, S. S., Ramakrishnan, S., & Gupta, P. C. (2005). Tobacco-specific nitrosamines in smokeless tobacco products marketed in India. International Journal of Cancer, 116, 16-19. doi:10.1002/ijc.20966.
27. Stepanov, I., Jensen, J., Hatsukami, D., & Hecht, S. S. (2006). Tobacco-specific nitrosamines in new tobacco products. Nicotine & Tobacco Research, 8, 309-313. doi:10.1080/14622200500490151.
28. Stepanov, I., Jensen, J., Hatsukami, D., & Hecht, S. S. (2008). New and traditional smokeless tobacco: Comparison of toxicant and carcinogen levels. Nicotine & Tobacco Research, 10, 1773-1782. doi:10.1080/14622200802443544.